Notably, Moderna said its Covid vaccine has won 45% of the U.S. market share so far this fall, up from the 36% market share it captured in 2022. Bancel added that company expects the U.S. market for Covid shots to be at least 50 million doses this fall, which is consistent with last year and is "something we repeat again in 2024." "Our assumption is everyone who has gotten their booster in 2023 will at least get their booster also in 2024 and beyond," Moderna CCO Arpa Garay said during the earnings call.